SHANGHAI, Jan. 26, 2026 /PRNewswire/ -- WuXi Biologics (2269.HK), a global leading Contract Research, Development and Manufacturing Organization (CRDMO), and HanchorBio Inc. (TPEx: 7827), a global clinical-stage biotechnology company advancing next-generation immunotherapies for oncology and autoimmune diseases, jointly announced today the signing of a strategic collaboration agreement on the development and manufacturing of multiple next-generation bi-/multi-functional fusion programs from HanchorBio's pipeline.

Under the agreement, WuXi Biologics will provide integrated, end-to-end biologics development and manufacturing services, including cell line development, process and bioassay development, drug product formulation development, and GMP manufacturing. The collaboration is designed to enhance CMC execution efficiency, accelerate clinical translation, and support scalable global development and manufacturing of HanchorBio's innovative fusion protein portfolio derived from its Fc-Based Designer Biologics (FBDB™) platform.

This partnership reflects HanchorBio's strategy to advance its platform-derived, multi-asset pipelines with development speed, manufacturing robustness, and capital efficiency from early clinical stages through commercialization. By leveraging WuXi Biologics' proven capabilities in complex biologics and its global quality systems, HanchorBio aims to shorten development timelines and maintain flexibility across multiple clinical programs.

WuXi Biologics brings extensive experience in complex modalities, including bispecific and multi-specific antibodies, antibody-drug conjugates (ADCs), and fusion proteins. As of 2025, there are 945 projects on WuXi Biologics' integrated platform, with approximately 60% are bi- and multi-specific antibodies, ADCs and fusion proteins, underscoring its track record in enabling accelerated development and manufacturing of advanced therapeutic modalities. Its proprietary technology platforms, such as WuXia™ TrueSite - targeted integration (TI)-based CHO cell line platform, and WuXiHigh^TM - high-throughput formulation development platform, are designed to enhance speed, quality, and scalability.

For HanchorBio, the collaboration supports continued expansion of its proprietary FBDB™ technology platform, which enables the rational design of multi-functional fusion proteins intended to modulate both innate and adaptive immunity. The partnership represents a significant step in aligning discovery innovation with industrial-scale and globally compliant execution as HanchorBio advances its oncology and autoimmune pipelines toward global clinical development.

Dr. Chris Chen, Chief Executive Officer of WuXi Biologics, said: " We are excited to embark on this collaboration with HanchorBio, which underscores the strong trust they placed in WuXi Biologics' comprehensive, end-to-end capabilities for developing next-generation biologics, especially complex molecules. By leveraging our industry-leading technology platforms, proven expertise, and unwavering commitment to quality, we strive to accelerate the development of HanchorBio's innovative bi-/multi-fusion proteins and help bring transformative therapies to patients worldwide."

Dr. Scott Liu, Founder, Chairman, and Chief Executive Officer of HanchorBio, commented: "This partnership with WuXi Biologics strengthens our ability to translate platform-driven innovation into high-quality clinical and commercial assets. As we advance multiple next-generation fusion protein programs, execution speed, manufacturing reliability, and scalability are critical. WuXi Biologics' proven expertise in complex biologics and global development makes them a strong strategic partner as we build a differentiated, multi-asset immunotherapy pipeline."

About WuXi Biologics

WuXi Biologics (stock code: 2269.HK) is a leading global Contract Research, Development and Manufacturing Organization (CRDMO) offering end-to-end solutions that enable partners to discover, develop and manufacture biologics – from concept to commercialization – for the benefit of patients worldwide.

With over 12,000 skilled employees in China, the United States, Ireland, Germany, Singapore and Qatar, WuXi Biologics leverages its technologies and expertise to provide customers with efficient and cost-effective biologics discovery, development and manufacturing solutions. As of December 31, 2025, WuXi Biologics is supporting 945 integrated client projects, including 74 in Phase III and 25 in commercial manufacturing.

WuXi Biologics regards sustainability as the cornerstone of long-term business growth. The company continuously drives green technology innovations to offer advanced end-to-end Green CRDMO solutions for its global partners while consistently achieving excellence in Environment, Social and Governance (ESG). Committed to creating shared value, it collaborates with all stakeholders to foster positive social and environmental impacts and promote responsible practices that empower the entire value chain.

For more information about WuXi Biologics, please visit: www.wuxibiologics.com. 

Contacts
Media
[email protected]
Business
[email protected]

About HanchorBio

Based in Taipei, Shanghai, and the San Francisco Bay Area, HanchorBio (TPEx: 7827) is a global clinical-stage biotechnology company focused on immuno-oncology and immune-mediated diseases. The company is led by an experienced team with a proven track record in biologics discovery and global development, aiming to reshape the landscape of cancer therapies. HanchorBio's proprietary Fc-based designer biologics (FBDB™) platform enables the design of multi-functional biologics with diverse targeting modalities, aiming to activate both innate and adaptive immune pathways to overcome the current challenges of anti-PD1/L1 immunotherapies. The FBDB™ platform has successfully delivered proof-of-concept data in several in vivo tumor animal models. HanchorBio is advancing a portfolio of innovative biologics designed to address significant unmet medical needs through differentiated molecular configurations in R&D and scalable CMC strategies. For more information, please visit: https://www.HanchorBio.com 

Contacts
[email protected] 

Ranks as China's Most Valuable Insurance Brand for the Tenth Consecutive Year

HONG KONG and SHANGHAI, Jan. 26, 2026 /PRNewswire/ -- Ping An Insurance (Group) Company of China, Ltd. ("Ping An" or "the Group"; HKEX: 2318/82318; SSE: 601318) has once again been named China's most valuable insurance brand for the tenth consecutive year, according to Brand Finance's Global 500 2026 report released on January 21. Ping An's brand value reached USD 48.839 billion, growing 13% year-on-year. The Group ranked 32^nd globally, up three places from 2025, and 10^th among Chinese brands. This marks the tenth consecutive year that Ping An has been recognized as China's most valuable insurance brand. Brand Finance highlighted Ping An's strong operational resilience and long–term value creation despite a complex and evolving external environment.

Brand Finance's Global 500 2026 ranking evaluates more than 6,000 brands worldwide across multiple dimensions, including brand strength, financial performance, and future growth potential. This year, 68 Chinese companies were listed. The top ten Chinese brands include Douyin, State Grid Corporation of China, Industrial and Commercial Bank of China, China Construction Bank Corporation, Bank of China, Agricultural Bank of China, Moutai, Tencent, China Mobile, and Ping An.

Ping An continues to advance its dual-pronged strategy of "Integrated Finance + Healthcare and Senior Care", driving high–quality growth. As of September 30, 2025, the Group recorded operating revenue of RMB 901,668 million. Operating profit attributable to shareholders of the parent reached RMB 116,264 million, a 7.2% year–on–year increase, while net profit attributable to shareholders of the parent rose 11.5% year-on-year to RMB 132,856 million. By the end of September 2025, Ping An served nearly 250 million retail customers, equivalent to one in six of the Chinese population. The retention rate of customers served for five years or more reached 94.4%, reflecting deep and sustained trust in Ping An brand.

Technology-Enabled Growth 

Ping An's technology capabilities continue to expand, with databases containing 30 trillion bytes of data, covering nearly 250 million retail customers. The Group is deepening and broadening its application of technology across real–world scenarios, empowering its financial businesses to enhance customer experience, strengthen risk management, reduce costs, and promote sales. These advances provide a strong and resilient technological foundation to support the development of the Ping An brand.

• Improving experience: Ping An Life's "111 Quick Claims" model enabled 58% of claims to be settled instantly in the first three quarters of 2025.
• Managing risks: AI-powered tools enhanced Ping An's risk management capabilities. Its Property & Casualty Insurance's anti-fraud intelligent claims interception reduced losses by RMB 9.15 billion in the first three quarters of 2025.
• Cutting costs: Ping An's AI service representatives handled more than 1.292 billion service interactions, 80% of total customer service volume, in the first three quarters of 2025.
• Boosting sales: The smart "AI + Human" reinstatement task assignment system helped increase policy reinstatement by 23%, improving protection continuity for customers.

Commitment to Sustainability

Ping An actively fulfills its social responsibilities, supporting green development and rural revitalization. In the first three quarters of 2025, the Group recorded RMB 55,279 million in green insurance premium income and provided RMB 47,390 million in funding to support rural industrial development. Due to its outstanding sustainability performance, Ping An received an MSCI AAA ESG rating, ranking No. 1 in the Asia–Pacific region in the "Multi-Line Insurance & Brokerage Industry".

Looking ahead, Ping An stated that it will remain customer-oriented and continue deepening its technology-enabled "Integrated Finance + Healthcare and Senior Care" strategy. By strengthening core competitiveness through differentiated services, the Group aims to meet the evolving financial, healthcare, and senior care needs arising from economic and social development together with growing public expectations.

About Ping An Insurance (Group) Company of China, Ltd.

Ping An Insurance (Group) Company of China, Ltd. (HKEX:2318 / 82318; SSE:601318) is one of the largest financial services companies in the world. It strives to become a world-leading provider of integrated finance, health and senior care services. Under the technology-enabled "integrated finance + health and senior care" dual-pronged strategy, the Group provides professional "financial advisory, family doctor, and senior care concierge" services to its nearly 250 million retail customers. Ping An advances intelligent digital transformation and employs technologies to improve financial businesses' quality and efficiency and enhance risk management. The Group is listed on the stock exchanges in Hong Kong and Shanghai. As of the end of December 2024, Ping An had more than RMB12 trillion in total assets. The Group ranked 27th in the Forbes Global 2000 list in 2025, 47th in the Fortune Global 500 list in 2025, and ranked AAA in MSCI ESG Ratings in 2025

For more information, please visit the www.group.pingan.com and follow our LinkedIn page - PING AN.

South Korea's Samsung Electronics (005930.KS) is close to obtaining Nvidia's (NVDA.US) certification for its latest AI memory chip, known as HBM4, Bloomberg reported, citing sources.

This development is anticipated to help narrow the gap with competitor SK Hynix (000660.KS). Samsung Electronics' stock opened higher today (26th) but has since ebbed back, last down 0.1%, while SK Hynix was down 2.9%.

Samsung Electronics entered the final certification stage with Nvidia, having provided initial samples to Nvidia last September, the report revealed, citing people with the knowledge of the matter. Nvidia uses a large amount of HBM to power its AI accelerators.

In the field of AI memory, Samsung lags behind SK Hynix and Micron (MU.US), but the stock prices of all three companies have skyrocketed in recent weeks as the AI ​​boom has led to a memory chip woe across the entire electronics industry.
~



AASTOCKS Financial News
Website: www.aastocks.com

瑞士達沃斯2026年1月24日 /美通社/ -- 世界經濟論壇年會期間，艾倫•麥克阿瑟基金會（EMF）發布《循環領跑未來：釋放動力電池與關鍵礦產循環經濟價值》研究報告（以下簡稱「報告」）。作為「全球能源循環計劃」啟動以來的最重要落地成果之一，該報告為全球動力電池的循環發展提供了首個可執行的行動路線圖。

報告由寧德時代、捷豹路虎(Jaguar Land Rover)、敦豪(DHL)、阿科瑪(Arkema)等全球領先企業以及全球電池聯盟(GBA)、巴塞爾公約亞太區域中心、中汽數據動力電池研究室等研究機構在內的30余家參與方共同支持，覆蓋新能源產業鏈上下游核心環。

寧德時代副總經理、董事會秘書蔣理表示：「報告凝聚了產業鏈上下游共識，為電池循環經濟提供了系統性的行動框架。」

報告指出，全球能源轉型正在重構汽車產業價值鏈，從「以燃料為核心」轉向「以材料為核心」。在這一背景下，推動循環經濟轉型，將重塑動力電池價值體系，釋放經濟價值，增強產業鏈韌性，減少對環境和社會的負面影響。報告認為，推動電池循環經濟的規模化轉型，需要從「小修小補」和「末端治理」轉向系統層面的重塑。

報告提出了五大領導力行動，為全行業提供一套兼具實操性與商業可行性的戰略指引，具體內容包括：

一、為循環而設計，摒棄線性思維。將易拆解、可診斷、可維修和再制造融入電池設計理念，延長電池使用壽命，提高回收率，讓電池成為可循環的、擁有多個生命周期的高價值資產。

二、優化交通與能源系統，重塑電池價值。優化充換電基建與共享出行網絡，消除裡程焦慮，讓電池適配合理容量，並兼具V2G等電網調峰能力，最大化利用資源。

三、規模化推廣循環商業模式。依托電池即服務（BaaS）等模式，將電池轉化為長期運營資產，實現多次循環利用，挖掘全生命周期商業價值。

四、共投共建區域性循環基礎設施。通過聯合投資、長期合作等方式，構建電池循環利用網絡，讓材料流轉高效、穩定、可追溯。

五、推動循環體系高效運轉。推廣電池護照等數字化工具，提升透明度，統一跨境流通規則，消除政策壁壘，讓電池資產在全球范圍內順暢流轉。

「五大領導力行動」獲得了產業界的積極響應。沃爾沃汽車全球可持續發展負責人Vanessa Butani指出，電動化必須與循環經濟協同推進。他認為，循環經濟可有效降低行業系統性風險、保障資源穩定性，並加快向碳中和出行體系的轉型，讓消費者受益於更加耐用、負責任生產的汽車產品。

蔣理表示，寧德時代已率先踐行五大領導力行動，打造了完整的循環閉環體系，貫穿電池研發、材料使用、商業應用、回收和再利用的全生命周期。

當前，寧德時代制定了行業最大規模的碳中和戰略。到2025年底，公司已將所有電池工廠打造為零碳工廠，實現核心運營碳中和。目前，公司已進入碳中和第二階段，致力於在2035年推動產業上下游實現價值鏈碳中和。

在回收端，寧德時代已實現鎳、鈷、錳回收率達99.6%，鋰回收率達96.5%，並通過全球1200家「寧家服務」網點建立了高效的回收體系。

在材料創新方面，寧德時代正在大力研發及應用碳排放更低的鈉離子電池，從源頭減少對稀缺礦產的依賴。鈉離子電池全生命周期碳排放較鋰電池最高可降低60%，2026年，鈉電池將在換電、乘用車、商用車和儲能等領域實現大規模應用。

在循環基礎設施方面，寧德時代通過「巧克力換電」及「騏驥換電」大力推廣車電分離模式，將電池轉化為專業管理的可運營資產，從根本上解決了退役電池回收渠道碎片化的難題。目前，公司已布局超1300座乘用車和商用車換電站，聯合超100家伙伴組建「巧克力換電聯盟」，構建「車電分離」網絡，為電池資產的集中管理與規模化回收奠定了基礎。

此外，在數據治理層面，作為全球電池聯盟（GBA）董事會成員，寧德時代積極試點「電池護照」大幅提升供應鏈的透明度與可追溯性。

作為這一系列產業實踐背後的重要推動力，「全球能源循環計劃」由寧德時代與艾倫•麥克阿瑟基金會於2025年3月共同發起。同年6月，「全球能源循環計劃」願景發布：匯聚產業鏈上下游、政府及學術機構等多方力量，共同推動電池循環經濟全面落地，同時助力新電池生產徹底擺脫對原生礦產資源的依賴。此次報告的發布，將上述願景進一步轉化為可執行的行動路線圖，為價值鏈各方的協同行動明確了方向。

未來，各方將持續推動循環經濟路線圖在不同國家和地區開展試點。推動全球電動汽車行業從「開采-制造-廢棄」的舊模式，轉向「設計-制造-使用-回收-再利用」的循環新模式。

DAVOS, Switzerland, Jan. 24, 2026 /PRNewswire/ -- Leading The Charge – Turning risk into reward with a circular economy for EV batteries and critical minerals, a whitepaper released by the Ellen MacArthur Foundation during the World Economic Forum Annual Meeting 2026, marks the first integrated, actionable circular value-chain roadmap for EV batteries grounded in real-world industrial practice. It also sets a landmark milestone in the cooperation between CATL and the Foundation.

Developed with input from over 30 leading organizations across the EV battery ecosystem — including CATL, DHL, Volvo, and JLR, alongside research institutions and NGOs — the report sets out a clear, industry-informed direction for how EV batteries must be designed, used, recovered, and reintegrated to maximise value and reduce systemic risk across the value chain.

As the founding strategic partner of The Foundation's Critical Minerals Mission, CATL worked closely with The Foundation and industry peers to translate circular economy principles into practical, deployable actions grounded in real operating experience. The roadmap also supports CATL's Global Energy Circularity Commitment, including its long-term goal to decouple battery growth from virgin raw material extraction.

It highlights the opportunities a circular EV battery system can unlock across environment, economy, product, and broader value creation. By keeping batteries and their critical minerals in use across multiple lifecycles, it reduces demand for newly mined materials, lowers emissions, and supports renewable energy integration. It also increases economic value by improving material efficiency, lowering waste and operational costs, and creating new revenue streams. At the same time, it strengthens supply chain resilience and distributes economic benefits more equitably across regions, showing that a systemic, circular approach transforms potential risks into strategic, value-generating opportunities.

Five bright spots to unlock a circular EV battery system
The whitepaper identifies five interdependent actions needed to keep battery materials in high-value use and strengthen system resilience:

1. Design batteries for circularity, not disposal
2. Rethink battery service within optimized energy–mobility systems
3. Scale circular business models that treat batteries as long-term assets
4. Build and co-invest in regional circular infrastructure
5. Enable a circular operating system through data, standards, and policy

CATL actions already in practice
CATL is already putting these system-level actions into practice across its operations. By separating the battery from the vehicle, CATL manages batteries as centrally managed assets, increasing utilization, enabling scheduled maintenance, and ensuring predictable return at end of use. Today, CATL operates more than 1,000 passenger-vehicle and over 300 commercial-vehicle swap stations, supported by a growing ecosystem of more than 100 partners.

This system integration enables high-quality recovery at scale. CATL's recycling operations achieve recovery rates of 99.6% for nickel, cobalt, and manganese, and 96.5% for lithium, with processing capacity expanding toward 270,000 tonnes per year. In parallel, CATL is applying alternative chemistries such as sodium-ion batteries, using widely available materials and reducing lifecycle carbon emissions per kilowatt-hour by up to 60%, reinforcing circular performance across mobility, swapping, and energy storage applications.

Scaling together
Speaking at The Foundation's Leadership Briefing among CATL Jiang Li, Vice-Chairman and Board Secretary of CATL highlighted: "This report marks a major milestone in the global journey towards a circular battery economy. Circular battery systems must now be scaled across regions, industries, and applications — from EVs to energy storage — and adapted to diverse market contexts."

"As EV adoption accelerates, a circular economy for batteries and critical minerals is no longer optional — it is essential to affordability, resilience, and long-term growth while reducing environmental and social impacts," said Wen-Yu Weng, Executive Leader for Critical Minerals at the Ellen MacArthur Foundation. "EV batteries are strategic assets, and circular approaches are key to retaining their value and ensuring critical minerals never become waste. We welcome CATL's contribution and look forward to continued collaboration to help scale a truly circular battery system and support the wider energy transition."

For CATL, this agenda directly underpins its pathway to carbon neutrality — building on the achievement of carbon neutrality across all its battery plants, and its target to achieve carbon neutrality across the full value chain by 2035.

The launch of the report marks an early milestone in CATL and The Foundation's broader collaboration to accelerate circularity of critical minerals. The next phase will focus on stress-testing these approaches in real-world environments, to understand how design, use, life extension, collection, and recycling loops function together at scale.

深圳2026年1月23日 /美通社/ -- 近日，晶泰科技（2228.HK）孵化企業萊芒生物在第 44 屆摩根大通醫療健康年會（J.P. Morgan Healthcare Conference）發表演講，並向全球投資者展示了其極低劑量 CAR-T 療法的研究者發起臨床（IIT）最新成果。在晶泰科技的研發助力下，萊芒生物基於其 AI+免疫代謝重編程平台，已經開發了多條研發管線。其中代謝增強型 CD19 CAR-T 療法，以低至常規 CAR-T 治療劑量千分之一（1‰）的極低劑量，實現多位系統性紅斑狼瘡患者完全緩解出院（100% CR），展示了未來「門診式」 CAR-T 治療的全新可能。同時，這一療法已助數十位復發難治性白血病/淋巴瘤患者達到 CR，並有多個實體瘤領域 IIT 臨床正在開展或即將啟動。這一系列進展再次印證了晶泰科技研發平台在賦能顛覆性技術、加速臨床轉化方面的卓越能力。

在晶泰科技的投資孵化與研發賦能下，萊芒生物聚焦創新腫瘤免疫治療藥物管線的研發，開發並持續升級其獨有的 META 10 代謝重編程技術平台。兩家公司還合作開發了 META 10-AI 平台，結合晶泰科技的AI算法與高通量篩選實驗，對代謝增強型 CAR-T 療法中用到的核心代謝增強因子進行了優化設計，使其獲得親和力的數百倍提高；團隊還打造了 AI 訓練的「超高清顯微鏡」，精準識別腫瘤標記與健康標記間僅 1 個氨基酸之差的細微特徵差異抗體，顯著提升CAR-T 療法與受體結合的親和力、特異性和免疫學活性，在「高效殺敵」的同時避免錯傷，盡可能降低毒副作用，帶來更優越的療效與安全性。目前相關結果已經申請中國專利，並應用於實體瘤靶點的代謝增強型 CAR-T 管線研發中，大幅提高 CAR-T 細胞在實體瘤免疫微環境的抗耗竭能力。

AI+免疫代謝重編程, 破解 CAR-T 治療瓶頸

據 Grand View Research 估計，全球 CAR-T 治療的市場規模在 2024 年為 46.5 億美元，並將以 22.2% 的年複合增長率在 2030 年達到 159.7 億美元。當前 CAR-T 療法在血液瘤領域雖已取得一定成效，但仍面臨著復發率高、實體瘤響應有限、成本高昂三大挑戰，其根源在於 T 細胞在持續抗腫瘤過程中易進入 「終末耗竭」 狀態，喪失增殖與殺傷能力，並對 PD-1/PD-L1 等免疫檢查點抑制劑無響應。

萊芒生物是晶泰科技於 2022 年孵化投資的創新企業，其創始團隊來自全球頂尖理工院校瑞士洛桑聯邦理工學院（EPFL）。通過與晶泰科技的深度研發合作，萊芒生物開發了其獨有的 META 10 與 META 10-AI 兩大 AI+代謝重編程技術平台，實現對耗竭 T 細胞代謝的精準調控，從而顯著增強其增殖能力、細胞殺傷活性及免疫記憶功能，以更低劑量、更低價快速的制備過程，實現更高的臨床響應率和更優的安全性，推動患者達到完全緩解，為患者提供更理想的細胞治療選擇。

血液瘤與自身免疫疾病臨床雙重突破

在晶泰科技的助力下，萊芒生物開發的代謝增強型 CD19 CAR-T療法，在自免性疾病和血液瘤領域展現出突破性治療潛力。2025 年，萊芒生物啟動了針對系統性紅斑狼瘡（SLE）的 IIT 臨床研究，取得重要進展。該療法以僅為常規 CAR-T 治療劑量千分之一（1‰）的極低劑量，在無需清淋預處理、無需中斷原有免疫抑製藥物、且住院時間顯著縮短的條件下，成功使多例中重度 SLE 患者實現無藥物依賴的完全緩解（100% CR）。基於良好的安全性數據，代謝增強型 CD19 CAR-T 療法有望支持門診式給藥模式，為自身免疫性疾病提供一種更便捷、更安全的 「免疫重置」 治療新範式。

在惡性血液瘤領域的 IIT 臨床中，代謝增強型 CD19 CAR-T療法同樣表現亮眼。首批入組治療的 20 餘名復發難治性白血病/淋巴瘤患者亦全部達到完全緩解（100% CR）狀態並順利出院。此外，本研究還成功覆蓋兒童患者以及對傳統 CAR-T 療法反應欠佳的慢性淋巴瘤患者群體，首位入組患兒及慢性淋巴瘤患者均達到 CR。安全性方面，在治療過程中患者體征平穩可控，未發現由治療引起的嚴重的細胞因子風暴、嚴重神經毒性等 CAR-T 治療的常見副作用。

平台技術, 重塑細胞治療經濟性與可及性

萊芒生物相關臨床研究榮獲 2025 年全國顛覆性技術創新大賽最高獎——「榮譽獎」，並獲得國家重點研發計劃顛覆性技術創新重點專項資助。這一進展有望改變現有 CAR-T 治療「百萬一針」、響應率低、毒副作用顯著的現狀，並利用小型自動化設備實現快速生產與成本的進一步降低，為安全高效的新一代 「平價」 CAR-T 療法上市乃至進入醫保奠定基礎，推動細胞治療從 「治療」 向 「治癒」，從 「集中生產」 向 「門診制備」 的重要跨越。

除血液瘤與自身免疫性疾病外，萊芒生物正將 META 10 平台拓展至實體瘤等領域。針對宮頸癌、肝癌、膽管癌等實體瘤適應症的代謝增強型細胞療法已經進入 IIT 臨床研究階段，正在進行患者招募和入組治療。針對 EGFR vIII 陽性膠質母細胞瘤與 GPC3 陽性肝細胞癌的 IL-10 CAR-T 療法已進入 IIT 臨床準備階段，預計 2026 年第一季度啟動 IIT 臨床研究。

值得一提的是，萊芒生物的 META 10 技術平台具有高度兼容性，不僅適用於自體 CAR-T，還可拓展至 in vivo CAR-T、TCR-T、TILs 等多種細胞治療形式，具備為合作夥伴提供即插即用解決方案的潛力。這種技術的靈活性與可擴展性使其成為細胞治療領域的 「通用型引擎」，能夠快速推動治療管線的升級與擴展。

萊芒生物的飛速發展及其在 CAR-T 療法上取得的系列突破性成果，是晶泰科技 「AI+機器人」 賦能平台成功孵化的又一力證。晶泰科技不僅為萊芒生物提供了關鍵的資金支持，更通過其行業領先的 AI 藥物研發平台能力，深度參與了萊芒核心平台（META 10, META 10-AI）的開發與持續優化升級，加速了其管線的開發進程。萊芒生物在血液瘤、自身免疫性疾病領域的突破性臨床成果，以及在實體瘤領域的快速推進，展現了其巨大的臨床價值和商業潛力。晶泰科技將持續賦能像萊芒生物這樣的前沿企業，孵化更多顛覆性療法，引領生物醫藥源頭創新。

關於萊芒生物 

深圳萊芒生物科技有限公司（Leman Biotech Co., Ltd）是一家處於臨床階段的免疫代謝創新藥物研發公司，由瑞士洛桑聯邦理工學院（EPFL）唐力教授團隊聯合晶泰科技共同創立。基於免疫代謝重編程（META 10）+前沿人工智能（AI）的創新技術，公司專注於研發代謝增強型腫瘤免疫治療藥物。公司核心技術META 10展示出治癒實體腫瘤的巨大潛力，相關成果發表於 Nature、Nature Biotechnology、Nature Immunology、Lancet Haematology 等國際頂級學術期刊，並申請了多項 PCT 專利和中國發明專利。

目前公司發展迅速，70% 高層次研發人員來自國內外名校並具有豐富的產業化經驗，多條研發管線進展順利。其中代謝增強型 CAR-T 細胞治療正在開展 IIT 臨床研究（NCT05715606, NCT05747157, NCT06120166），20 餘位患者獲得完全緩解並出院。2022 年以來，公司累計獲得超 4 億元風險投資和項目資助，榮獲 20 余項生物醫藥領域國家或省市級獎項，並獲得美國基因與細胞治療協會（ASGCT 2024）和美國癌症協會（AACR 2024）最新突破性（Late-Breaking）進展口頭報告（全國唯一）。萊芒生物，源自瑞士，致力於突破免疫治療的瓶頸難題，提高免疫治療的響應率和療效，為實現治癒腫瘤的終極目標而不懈奮鬥！

關於晶泰科技

晶泰科技（「XtalPi Holdings Limited」，股份簡稱：晶泰控股，XTALPI，股票代碼：2228.HK）由三位麻省理工學院的物理學家於 2015 年創立，是一個基於量子物理、以人工智能賦能和機器人驅動的創新型研發平台。公司採用基於量子物理的第一性原理計算、人工智能、高性能雲計算以及可擴展及標準化的機器人自動化相結合的方式，為製藥及材料科學（包括農業技術、能源及新型化學品以及化妝品）等產業的全球和國內公司提供藥物及材料科學研發解決方案及服務。

Alphabet (GOOGL.US) is scheduled to announce its 4Q25 results on 4 February (Wednesday), Citi Research issued a research report saying.

With the release of Gemini 3 and Personal Intelligence, along with the newly announced partnership with Apple, Gemini's product strategy is accelerating, Citi Research added. It is believed that Google's assets will further expand its market share.

The broker also believed that, as its AI strategy continues to evolve with continuous improvement in operational efficiency, Alphabet's competitive market position is becoming increasingly solid.

Therefore, Alphabet remains Citi Research's top pick in the internet sector, with rating reiterated at Buy and a target price of US$350.
~


AAStocks Financial News
Website: www.aastocks.com

Citi Research issued a research report expecting that Amazon.com (AMZN.US)'s upcoming 4Q25 results will beat market consensus in terms of revenue and operating profit.

Specifically, its AWS revenue growth is anticipated to accelerate to 22.5% YoY in 4Q25, primarily driven by broader collaborations in the AI sector and the expansion of infrastructure.

In the retail segment, third-party data and Citi credit card data indicate a strong performance during the online holiday shopping season, suggesting that Amazon.com will continue to gain market share.

Considering the accelerated AWS revenue growth, the continued expansion of consumption share and margin expansion, Amazon.com remains Amazon.com's top pick in the internet sector, with rating reiterated at Buy and a target price of US$320.
~

AASTOCKS Financial News
Website: www.aastocks.com

The total retail sales for passenger cars market in narrow sense in Mainland China in January is expected to be around 1.8 million units, representing an MoM decline of 20.4% and a YoY growth of 0.3%, China Passenger Car Association (CPCA) preliminary data showed.

Among them, new energy vehicle retail sales are expected to reach approximately 800,000 units, with a penetration rate of about 44.4%.
~

AASTOCKS Financial News
Website: www.aastocks.com

US bourse sustained its uptrend on Thursday amid de-fused geopolitical concerns, and the in-line US core PCE price increase for November. The DJIA spiked by as much as 530 points to a peak of 49,607, closing up 306 points or 0.6% at 49,384. The Nasdaq closed up 211 points or 0.9% at 23,436. The S&P 500 added 37 points or 0.6% to end at 6,913.

Big techs thrived, with Meta (META.US) up 5.7%. Tesla (TSLA.US) jumped up 4.2%, as the company plans to sell Optimus humanoid robots to the public as early as the end of next year. Amazon (AMZN.US) and Microsoft (MSFT.US) rose over 1%. Alphabet (GOOG.US), NVIDIA (NVDA.US), and Apple (AAPL.US) gained less than 1%.
~



AASTOCKS Financial News
Website: www.aastocks.com